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Pancreatic Acinar Cell Pathophysiology
FRED S. GORELICK, M.D.
The high level of interest in the pancreatic acinar cell over the past 25 years is a
reflection ofthe fact that this system is a paradigm for the study ofprotein synthesis,
sorting, and secretion. Moreover, pancreatic inflammation is a serious clinical
problem that may relate to a disorder in the basic organization of this cell. The
discussions byPandol, Steer, Grendell, and myselfare closelyrelatedbut alsocover a
spectrum ofinterests.
It is accepted that the level of intracellular calcium plays an important role in
mediatingneurohumorally regulated secretion from the pancreatic acinarcell. There
appear to be two components to this calcium response. The first is the release of
calcium from intracellular stores, and the second is dependent on the entry of
calcium across the plasma lemma from the external environment. Although a brief
secretory response is elicited in the absence of extracellular calcium, a prolonged
response requires the continued presence of extracellular calcium. It has become
clear, over the past several years, that the generation of these intracellular calcium
signals results from the summation of a diverse number of calcium regulatory
systems. These systems include: (1) mechanisms for releasing calcium from inositol
1,4,5-trisphosphate-sensitive (IP3) and -insensitive pools; (2) calcium-induced cal-
cium intracellular release; (3) regulation ofcalcium entry; (4) regulation of calcium
egress; and (5) refilling of intracellular storage pools. Pandol's work reflects on the
potential importance ofcGMP in mediating this refilling process [1]. Such a role for
cGMP would not be totally surprising, since it can directly mediate calcium entry in
other systems [2].
In the pancreatic acinar cell, the initial rise in intracellular calcium after stimula-
tion is supplied from intracellular stores. It has been widely held that the generation
ofIP3 mediates this initial increase in calcium. The IP3 receptor has been character-
ized and is probably associated with a modified component of the endoplasmic
reticulum. One of the most interesting properties of this ligand-activated calcium
channel is the pattern of calcium release in response to IP3: in response to
stimulation, calcium release through this channel is discontinuous. Furthermore,
precise amounts ofcalcium are released with each round of IP3 stimulation [3]. The
purified reconstituted IP3 receptor also exhibits "quantal calcium release" and
confirms that this action is an intrinsic property of the receptor [3,4]; however, the
mechanism for this autoregulation is unknown.
Several types of studies have raised questions regarding the importance of
IP3-mediated calcium release and secretion in the pancreatic acinar cell [5]. This
concern is reflected in the observation that maximal secretory response is elicited
prior to a detectable increase in IP3. Some authors have suggested that another
soluble mediator may be responsible for stimulating the calcium release responsible
for secretion. Steer's group has provided some important insights regarding this
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question. They have demonstrated that a soluble mediator which releases calcium
from an IP3-insensitive pool is generated following acinar stimulation [5]. A very
recent study in pancreatic islets reports that cyclic ADP-ribose has the same role in
calcium release as that previously demonstrated for IP3 [6]. Although cyclic ADP-
ribose and IP3 both stimulate calcium release from a microsomal pool, they work
through different receptors. Additional studies will be required to identify this
messenger and to elucidate which components of the calcium response, including
oscillations andwaves, are linked to the secretory event aswell as the other effects of
neurohumoral stimulation described below.
It has been recognized for some time that the pancreas exhibits a distinct biphasic
secretory response in reaction to high doses of cholecystokinin or carbachol. The
reason for this biphasic response is unknown. Higher levels of intracellular calcium
and disorganization ofthe cytoskeleton are, however, associated with this inhibition.
As discussed, treatment of intact animals with high doses of these agents results in
pancreatitis. An interest of our laboratory has been to attempt to relate events that
take place in the acini to those responsible for the generation ofpancreatitis. Based
on observations in both humans and experimental models of pancreatitis, it is
believed that the intrapancreatic activation ofzymogens maybe avery early event in
the development ofpancreatitis. One potential site ofthis zymogen conversion may
be within the pancreatic acinar cell. Using an immunoblot assay that discriminates
between inactive zymogens and active enzyme forms, exposure of acini to high doses
of cholecystokinin (CCK) or carbachol was found to stimulate zymogen conversion.
Although small amounts of carboxypeptidase Al were detectable in the basal state,
none was detected for two other zymogens. An inhibitor ofsoluble guanylate cyclase
blocked this conversion, suggesting that a cGMP-mediated pathway is responsible.
Subsequent studies have found that the conversion is also dependent on calcium.
These observations are consistent with the conclusions of Pandol that link calcium
entry into the acinar cell with cGMP metabolism. Additional regulatory mechanisms
would have to be active, however, to generate the various responses observed after
treatment with maximal and supramaximal doses of secretagogue. One possibility is
that a graded calcium response (e.g., frequency or heightofoscillations, and the like)
activates different cellular events. For example, small increases in calcium may elicit
secretion; higher doses, zymogen conversion; and still higher doses, inhibited secre-
tion. Alternatively, different second messenger pathways may be stimulated at the
various doses of hormones. For example, although maximal doses of CCK have no
measurable effect on cAMP levels, exposure ofacinito supramaximal doses results in
a dramatic increase in cAMP levels. Further studies will be needed to define clearly
the second messenger pathway responsible for this conversion as well as the
intracellular site of conversion, determine if catalytically active enzymes are being
generated, and examine the relationship ofthis conversion to pancreatitis.
When animals or humans are exposed to very high doses of CCK or acetylcholine
(e.g., by exposure to cholinesterase inhibitors), enzyme secretion from the pancreas
is inhibited. Moreover, these conditions also generate pancreatitis. The mechanisms
responsible for generating this form of hyperstimulation pancreatitis have been
studied in detail by Steer and colleagues. One of the features of this form of
pancreatitis appears to be the redistribution of lysosomal enzymes to the secretory
compartment. Although there is some discussion on this topic, most would agree
that, under basal conditions, some lysosomal enzymes reside in the zymogen granule
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and that, under the conditions of pancreatitis, the amount of lysosomal enzymes in
this compartment increases. The potential importance ofthis observation to pancre-
atitis is that, under the appropriate conditions, the lysosomal enzyme cathepsin B
can activate trypsinogen. Thus, the sorting of lysosomal enzymes into the secretory
compartment may result in trypsinogen activation. There are, however, observations
that engender a certain level of caution prior to assigning such a role to lysosomal
enzymes. First, the enzymes are already present in the basal state and increase only
severalfold following the induction of pancreatitis [7]. Second, preliminary work
from Steer's group suggest that some treatments (e.g., chloroquine or obstruction)
may result in a redistribution of lysosomal enzymes, but not generate pancreatitis.
Finally, our group has observed that an inhibitor of lysosomal enzymes, including
cathepsin B (E64), failed to block the conversion ofzymogens in isolated acinar cells
[8]. Moreover, exposure ofacini tothese agents actually resultsin enhancedzymogen
conversion. This finding suggests that the role of the lysosomal hydrolases in the
secretory compartment may not be to activate trypsinogen, but rather to degrade
enzymes converted to their active forms. The mechanisms for maintaining lysosomal
enzymes in an apparently inactive state within the zymogen granule are unknown,
but may relate to pH or ionic conditionswithin that compartment. Irrespective ofthe
mechanism ofzymogen activationwithin the acinarcells, it isgenerallyaccepted that
an inhibition ofsecretion is also required to initiate injury.
One ofthe difficulties with the current experimental modelsofpancreatitis is their
relevance or resemblance to human disease. Steer's group reported that obstruction
ofthe pancreatic duct in opossum leads to a severe and sometimes fatal pancreatitis,
which is an important model for several reasons. First, it reflects the human
condition in which duct obstruction may lead to pancreatitis. Second, it is a
reproducible model of severe injury. Although the diet-induced model ofpancreati-
tis also generates a severe pancreatitis [9], the unclear relationship ofthis model to
human disease makes it considerably less desirable for study. Thus, the opossum
model should allow the investigator to test various interventions that may affect the
course ofsevere pancreatitis in a controlled manner.
Grendell comments on the use ofvarious receptor antagonists in the treatment of
pancreatitis. A growing number ofstudies (some ofwhich have been presented only
in abstract form) suggest that CCKreceptorblockade isbeneficial in the treatment of
a number of forms ofpancreatitis [10-12]. Although this CCK blockade is assumed
to be acting at the level of the pancreatic acinar cell, its site of action is not
definitively known. Even if the target is the acinar cell, the reason for this beneficial
effect is unknown. One consideration, however, is that during the course ofpancre-
atitis the acinar cell may become sensitized to the harmful effects of CCK. Thus,
lower doses ofCCK than the those required under normal conditions may stimulate
the zymogen conversion. Itwill be ofinterest to examine the effect ofthe potent and
specific CCK antagonists on the course ofpancreatitis induced in the opossum. The
role ofsomatostatin inthe treatment ofpancreatitis isjust as controversial. Although
somatostatin puts the pancreas to "rest," this approach to therapy has never been
shown tobebeneficial. Indeed, ifsomatostatinblocks the secretion ofactive enzymes
from the pancreatic acinarcell, it could even worsen the course ofacute pancreatitis.
Together, these studies have provided an update on the cellular mechanisms that
regulate the response of the pancreatic acinar cell to neurohumoral stimulation.
Several patterns of response have been observed and include stimulated enzyme
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secretion, intracellular conversion of zymogens, and high-dose inhibition of secre-
tion. Although the secretory response of the pancreas is undoubtedly linked to
intracellular calcium metabolism, the mechanisms regulating this calcium release
remain unclear. Furthermore, the messengers regulating the other stereotypical
responses of the acinar cell to stimulation are also unknown. One of the most
interesting potential links between experimental model systems and disease is
reflected by the CCK-induced conversion of zymogens within the pancreatic acinar
cell and pancreatitis. For a growing number of experimental systems, there is
compelling evidence that CCK may contribute to the injury. This evidence raises the
possibility that some conditions leading to pancreatitis may sensitize the acinar cell
to CCK and its effect on zymogen conversion. Furthermore, it suggests that CCK-
receptor blockade should be evaluated as a potential form of therapy for acute
pancreatitis.
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